Rita L Hui

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 12

Top Topics

Patients With Inflammatory Bowel Disease

Top Venues

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Crohn's & colitis 360

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

JCO oncology practice

This page only lists publications with an associated author ORCID identifier.

Publications

Helen W Wong, Vivian H Nguyen, Timothy Y Mok, Fang Niu, Merta Cushing, Michael Lam, Stephanie L Ho, Lisa Y Law, Ashraf R Aziz, Rita L Hui
Outcomes of Rituximab-abbs versus Rituximab in Patients with Diffuse Large B-Cell Lymphoma in a Noninferiority Study. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Shirley Ng, Nicholas Baker, Fang Niu, Jed A Katzel, Hanh T Bergere, Moshi Whang, Eric McGary, Raymond Liu, Kim Le, Rita L Hui
Impact of pharmacist managed oral epidermal growth factor receptor inhibitors. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)
Helen W Wong, Vivian H Nguyen, Timothy Y Mok, Fang Niu, Merta Cushing, Michael Lam, Stephanie L Ho, Lisa Y Law, Ashraf R Aziz, Rita L Hui
Outcomes of Rituximab-abbs versus Rituximab in Patients with Diffuse Large B-Cell Lymphoma in a Noninferiority Study. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2024)
Ye Ji Lee, Thomas Delate, Rita L Hui, Kim Le, Catherine Pham
Real-World Noninferiority Assessment of Two Filgrastim Biosimilars in Patients Receiving Myelosuppressive Chemotherapy. JCO oncology practice (2024)
Helen W Wong, Vivian H Nguyen, Timothy Y Mok, Fang Niu, Merta Cushing, Michael Lam, Stephanie L Ho, Lisa Y Law, Ashraf R Aziz, Rita L Hui
Outcomes of Rituximab-abbs versus Rituximab in Patients with Diffuse Large B-Cell Lymphoma in a Noninferiority Study. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Catherine Pham, Fang Niu, Thomas Delate, Gary L Buchschacher, Yan Li, Ekim Ekinci, Kim Le, Rita L Hui
Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2023)
Vanessa R Su Zhang, Fang Niu, Eric A Lee, Christopher DiStasio, Benjamin I Broder, Steven G Steinberg, Rita L Hui
Safety of baclofen versus tizanidine for older adults with musculoskeletal pain. Journal of the American Geriatrics Society (2023)
Lena Chaitesipaseut, Nina Shah, Thach-Giao Truong, Fang Niu, Patrick Shin, Kavita Sharma, Joshua Smith, Rita L Hui
Outcomes of weight-based vs. fixed dose of Pembrolizumab among patients with non-small cell lung cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)
Catherine Pham, Fang Niu, Rita L Hui, Kim N Le, Thomas Delate
Patient perceptions on switching from reference product adalimumab to biosimilar adalimumab-atto. Clinical rheumatology (2023)
Joshua T Smith, Fernando S Velayos, Fang Niu, Vincent Liu, Thomas Delate, Suresh Pola, Kim Le, Rita L Hui
Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States. Crohn's & colitis 360 3 (3) (2021)
Joshua T Smith, Fernando S Velayos, Fang Niu, Vincent Liu, Thomas Delate, Suresh Pola, Kim Le, Rita L Hui
Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States. Crohn's & colitis 360 3 (3) (2021)
Stephanie L Ho, Fang Niu, Suresh Pola, Fernando S Velayos, Xian Ning, Rita L Hui
Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 34 (3) (2021)